Log in

NYSE:CRY - Cryolife Stock Price, Forecast & News

$25.82
-0.24 (-0.92 %)
(As of 12/15/2019 04:00 PM ET)
Today's Range
$25.41
Now: $25.82
$26.15
50-Day Range
$22.08
MA: $24.30
$26.10
52-Week Range
$20.76
Now: $25.82
$33.00
Volume157,135 shs
Average Volume159,617 shs
Market Capitalization$968.25 million
P/E Ratio99.31
Dividend YieldN/A
Beta0.64
CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP22890310
Phone770-419-3355

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$262.84 million
Cash Flow$0.74 per share
Book Value$7.44 per share

Profitability

Net Income$-2,840,000.00

Miscellaneous

Employees1,100
Market Cap$968.25 million
Next Earnings Date2/12/2020 (Estimated)
OptionableOptionable

Receive CRY News and Ratings via Email

Sign-up to receive the latest news and ratings for CRY and its competitors with MarketBeat's FREE daily newsletter.


Cryolife (NYSE:CRY) Frequently Asked Questions

What is Cryolife's stock symbol?

Cryolife trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRY."

How were Cryolife's earnings last quarter?

Cryolife Inc (NYSE:CRY) released its quarterly earnings data on Wednesday, October, 30th. The medical equipment provider reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. The medical equipment provider had revenue of $67.90 million for the quarter, compared to analyst estimates of $68.28 million. Cryolife had a return on equity of 3.50% and a net margin of 0.24%. Cryolife's revenue was up 5.1% compared to the same quarter last year. During the same period last year, the firm posted $0.08 earnings per share. View Cryolife's Earnings History.

When is Cryolife's next earnings date?

Cryolife is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Cryolife.

What guidance has Cryolife issued on next quarter's earnings?

Cryolife updated its FY19 earnings guidance on Wednesday, October, 30th. The company provided EPS guidance of $0.28-0.32 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.30. The company issued revenue guidance of $276.5-278.5 million, compared to the consensus revenue estimate of $281.33 million.

What price target have analysts set for CRY?

4 brokerages have issued twelve-month price objectives for Cryolife's shares. Their forecasts range from $30.00 to $35.00. On average, they anticipate Cryolife's share price to reach $32.75 in the next year. This suggests a possible upside of 26.8% from the stock's current price. View Analyst Price Targets for Cryolife.

What is the consensus analysts' recommendation for Cryolife?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cryolife in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cryolife.

What are Wall Street analysts saying about Cryolife stock?

Here are some recent quotes from research analysts about Cryolife stock:
  • 1. According to Zacks Investment Research, "CryoLife, Inc. is a leader in medical device manufacturing and distribution and in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries. It operates throughout the U.S. and internationally. CryoLife manufactures and distributes BioGlue Surgical Adhesive, an FDA-approved adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in Europe for use in soft tissue repair and has received additional marketing approvals in several other countries throughout the world. CryoLife's BioFoam Surgical Matrix is CE marked in Europe for use as an adjunct to hemostasis in cardiovascular surgery and on abdominal parenchymal tissues (liver and spleen) when control of bleeding by ligature or conventional methods is ineffective or impractical. CryoLife distributes PerClot, a powdered hemostat, in Europe and other select international countries. " (10/23/2019)
  • 2. Needham & Company LLC analysts commented, "CRY has undergone a transition into a higher growth company with two major acquisitions since 2015. We believe that it has a full pipeline including 13 new products and indications but we don’t expect these to begin to translate to stronger revenue growth until 2020. And 2019 appears to be a transition year from an earnings and margin perspective. Given all of this, and our belief that CRY shares are fairly valued, we initiate coverage with a Hold rating." (2/27/2019)

Has Cryolife been receiving favorable news coverage?

Media stories about CRY stock have trended neutral on Sunday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cryolife earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave news coverage about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Cryolife.

Are investors shorting Cryolife?

Cryolife saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 916,800 shares, an increase of 18.1% from the October 31st total of 776,100 shares. Based on an average trading volume of 211,100 shares, the short-interest ratio is currently 4.3 days. Currently, 2.6% of the company's shares are short sold. View Cryolife's Current Options Chain.

Who are some of Cryolife's key competitors?

What other stocks do shareholders of Cryolife own?

Who are Cryolife's key executives?

Cryolife's management team includes the folowing people:
  • Mr. James Patrick MacKin, Chairman, Pres & CEO (Age 52)
  • Mr. David Ashley Lee CPA, CPA, Exec. VP, COO & CFO (Age 54)
  • Ms. Jean F. Holloway, Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 62)
  • Mr. John E. Davis, Sr. VP of Global Sales & Marketing (Age 54)
  • Ms. Amy D. Horton CPA, CPA, VP & Chief Accounting Officer (Age 49)

Who are Cryolife's major shareholders?

Cryolife's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (3.20%), Monarch Partners Asset Management LLC (0.69%), Rhumbline Advisers (0.29%), New York State Teachers Retirement System (0.25%), Dupont Capital Management Corp (0.23%) and Connors Investor Services Inc. (0.22%). Company insiders that own Cryolife stock include Amy Horton, C Elkins Ronald, David Ashley Lee, Harvey Morgan, James P Mackin, Jean F Holloway, John E Davis, Ronald D Mccall and Scott B Capps. View Institutional Ownership Trends for Cryolife.

Which institutional investors are selling Cryolife stock?

CRY stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, State Street Corp, Barclays PLC, Squarepoint Ops LLC and NBW Capital LLC. Company insiders that have sold Cryolife company stock in the last year include Amy Horton, David Ashley Lee, James P Mackin, Jean F Holloway, Ronald D Mccall and Scott B Capps. View Insider Buying and Selling for Cryolife.

Which institutional investors are buying Cryolife stock?

CRY stock was purchased by a variety of institutional investors in the last quarter, including Dupont Capital Management Corp, Monarch Partners Asset Management LLC, State of Alaska Department of Revenue, Brasada Capital Management LP, Mackay Shields LLC, California Public Employees Retirement System, Rhumbline Advisers and First Trust Advisors LP. View Insider Buying and Selling for Cryolife.

How do I buy shares of Cryolife?

Shares of CRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cryolife's stock price today?

One share of CRY stock can currently be purchased for approximately $25.82.

How big of a company is Cryolife?

Cryolife has a market capitalization of $968.25 million and generates $262.84 million in revenue each year. The medical equipment provider earns $-2,840,000.00 in net income (profit) each year or $0.26 on an earnings per share basis. Cryolife employs 1,100 workers across the globe.View Additional Information About Cryolife.

What is Cryolife's official website?

The official website for Cryolife is http://www.cryolife.com/.

How can I contact Cryolife?

Cryolife's mailing address is 1655 Roberts Boulevard N.W, Kennesaw GA, 30144. The medical equipment provider can be reached via phone at 770-419-3355 or via email at [email protected]


MarketBeat Community Rating for Cryolife (NYSE CRY)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  317 (Vote Outperform)
Underperform Votes:  251 (Vote Underperform)
Total Votes:  568
MarketBeat's community ratings are surveys of what our community members think about Cryolife and other stocks. Vote "Outperform" if you believe CRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel